Status: Not yet recruiting
Study to Assess the Safety and Efficacy of DERMASEAL for the Treatment of Split-Thickness Skin Graft Donor Site Wounds
The goal of this study to determine whether the combination biologic/drug DERMASEAL will safely decrease donor wound pain after split-thickness skin graft surgery. Participants will have their skin graft donor sites immediately treated with DERMASEAL versus standard of care wound dressings followed by periodic monitoring of their recovery.
Participants needed: 12
Trial details
Phase: Phase 1, Phase 2Age: 21+Biological sex: AllType: InterventionalSponsor: Hobart W. HarrisUpdated: Jun 11, 2024
Eligibility criteria
Men or women ≥ 21 years of age. [+6]
Hypersensitivity to silver or fresh frozen plasma. [+10]